BioSpace News Archive

Lone Star Bio

Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer

Lumos Pharma, Inc., a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also as Dr. Duke, to the position of Chief Medical Officer, effective January 1, 2024.

January 4, 2024
·
5 min read
Biotech Bay

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, is hosting an investor webcast highlighting the significant potential of luveltamab tazevibulin, a novel folate receptor-α targeting ADC.

January 4, 2024
·
7 min read
Business

Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, announced the appointment of Minji Kim, Ph.D. as Chief Business Officer.

January 4, 2024
·
6 min read
Pharm Country

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Aprea Therapeutics, Inc. provided a corporate update highlighting recent developments and plans for advancement of its pipeline of DNA Damage Response anti-cancer agents in 2024.

January 4, 2024
·
8 min read
Biotech Bay

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry’s First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

Allogene Therapeutics, Inc. announced its 2024 Platform Vision that redefines the future of CAR T by leveraging the unique attributes of allogeneic CAR T products.

January 4, 2024
·
15 min read
Biotech Bay

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

Vaxcyte, Inc. announced an update regarding the ongoing progress of the Company’s pneumococcal conjugate vaccine franchise.

January 4, 2024
·
12 min read
Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates

Fusion Pharmaceuticals Inc. announced significant progress with its FPI-2265 development program, an update on FPI-1434 Phase 1 Cohort 2 data and the production of the first clinical doses at the Company’s proprietary manufacturing facility.

January 4, 2024
·
11 min read
Business

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

Novocure announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer.

January 4, 2024
·
5 min read
BioCapital

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Acumen Pharmaceuticals, Inc. announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 10:30 a.m. PT.

January 4, 2024
·
1 min read
BioMidwest

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

Allogene Therapeutics Inc. and Foresight Diagnostics announced a strategic partnership to develop a minimal residual disease in-vitro diagnostic to determine eligibility in ALPHA3, the first pivotal trial for first line consolidation treatment of large B-cell lymphoma.

January 4, 2024
·
10 min read